These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 35822095

  • 1. Method development and validation for analysis of phenylalanine, 4-hydroxyphenyllactic acid and 4-hydroxyphenylpyruvic acid in serum and urine.
    Hughes AT, Milan AM, Shweihdi E, Gallagher J, Ranganath L.
    JIMD Rep; 2022 Jul; 63(4):341-350. PubMed ID: 35822095
    [Abstract] [Full Text] [Related]

  • 2. Revisiting Quantification of Phenylalanine/Tyrosine Flux in the Ochronotic Pathway during Long-Term Nitisinone Treatment of Alkaptonuria.
    Ranganath LR, Hughes AT, Davison AS, Khedr M, Imrich R, Rudebeck M, Olsson B, Norman BP, Bou-Gharios G, Gallagher JA, Milan AM.
    Metabolites; 2022 Sep 29; 12(10):. PubMed ID: 36295821
    [Abstract] [Full Text] [Related]

  • 3. Interference of hydroxyphenylpyruvic acid, hydroxyphenyllactic acid and tyrosine on routine serum and urine clinical chemistry assays; implications for biochemical monitoring of patients with alkaptonuria treated with nitisinone.
    Curtis SL, Norman BP, Milan AM, Gallagher JA, Olsson B, Ranganath LR, Roberts NB.
    Clin Biochem; 2019 Sep 29; 71():24-30. PubMed ID: 31228435
    [Abstract] [Full Text] [Related]

  • 4. Quantification of the flux of tyrosine pathway metabolites during nitisinone treatment of Alkaptonuria.
    Milan AM, Hughes AT, Davison AS, Khedr M, Rovensky J, Psarelli EE, Cox TF, Rhodes NP, Gallagher JA, Ranganath LR.
    Sci Rep; 2019 Jul 11; 9(1):10024. PubMed ID: 31296884
    [Abstract] [Full Text] [Related]

  • 5. Urine homogentisic acid and tyrosine: simultaneous analysis by liquid chromatography tandem mass spectrometry.
    Hughes AT, Milan AM, Christensen P, Ross G, Davison AS, Gallagher JA, Dutton JJ, Ranganath LR.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jul 15; 963():106-12. PubMed ID: 24952314
    [Abstract] [Full Text] [Related]

  • 6. Comprehensive Biotransformation Analysis of Phenylalanine-Tyrosine Metabolism Reveals Alternative Routes of Metabolite Clearance in Nitisinone-Treated Alkaptonuria.
    Norman BP, Davison AS, Hickton B, Ross GA, Milan AM, Hughes AT, Wilson PJM, Sutherland H, Hughes JH, Roberts NB, Bou-Gharios G, Gallagher JA, Ranganath LR.
    Metabolites; 2022 Sep 29; 12(10):. PubMed ID: 36295829
    [Abstract] [Full Text] [Related]

  • 7. Hepatobiliary circulation and dominant urinary excretion of homogentisic acid in a mouse model of alkaptonuria.
    Norman BP, Sutherland H, Wilson PJM, Rutland DA, Milan AM, Hughes AT, Davison AS, Khedr M, Jarvis JC, Gallagher JA, Bou-Gharios G, Ranganath LR.
    J Inherit Metab Dis; 2024 Jul 29; 47(4):664-673. PubMed ID: 38487984
    [Abstract] [Full Text] [Related]

  • 8. Determinants of tyrosinaemia during nitisinone therapy in alkaptonuria.
    Ranganath LR, Milan AM, Hughes AT, Davison AS, M K, Norman BP, Bou-Gharios G, Gallagher JA, Imrich R, Arnoux JB, Rudebeck M, Olsson B.
    Sci Rep; 2022 Sep 27; 12(1):16083. PubMed ID: 36167967
    [Abstract] [Full Text] [Related]

  • 9. Serum markers in alkaptonuria: simultaneous analysis of homogentisic acid, tyrosine and nitisinone by liquid chromatography tandem mass spectrometry.
    Hughes AT, Milan AM, Davison AS, Christensen P, Ross G, Gallagher JA, Dutton JJ, Ranganath LR.
    Ann Clin Biochem; 2015 Sep 27; 52(Pt 5):597-605. PubMed ID: 25628464
    [Abstract] [Full Text] [Related]

  • 10. Comparing the Phenylalanine/Tyrosine Pathway and Related Factors between Keratopathy and No-Keratopathy Groups as Well as between Genders in Alkaptonuria during Nitisinone Treatment.
    Ranganath LR, Milan AM, Hughes AT, Davison AS, Khedr M, Imrich R, Rudebeck M, Olsson B, Norman BP, Bou-Gharios G, Gallagher JA.
    Metabolites; 2022 Aug 22; 12(8):. PubMed ID: 36005644
    [Abstract] [Full Text] [Related]

  • 11. Metabolomic studies in the inborn error of metabolism alkaptonuria reveal new biotransformations in tyrosine metabolism.
    Norman BP, Davison AS, Hughes JH, Sutherland H, Wilson PJ, Berry NG, Hughes AT, Milan AM, Jarvis JC, Roberts NB, Ranganath LR, Bou-Gharios G, Gallagher JA.
    Genes Dis; 2022 Jul 22; 9(4):1129-1142. PubMed ID: 35685462
    [Abstract] [Full Text] [Related]

  • 12. The effect of nitisinone on homogentisic acid and tyrosine: a two-year survey of patients attending the National Alkaptonuria Centre, Liverpool.
    Milan AM, Hughes AT, Davison AS, Devine J, Usher J, Curtis S, Khedr M, Gallagher JA, Ranganath LR.
    Ann Clin Biochem; 2017 May 22; 54(3):323-330. PubMed ID: 28081634
    [Abstract] [Full Text] [Related]

  • 13. Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone.
    Preston AJ, Keenan CM, Sutherland H, Wilson PJ, Wlodarski B, Taylor AM, Williams DP, Ranganath LR, Gallagher JA, Jarvis JC.
    Ann Rheum Dis; 2014 Jan 22; 73(1):284-9. PubMed ID: 23511227
    [Abstract] [Full Text] [Related]

  • 14. Nitisinone Arrests but Does Not Reverse Ochronosis in Alkaptonuric Mice.
    Keenan CM, Preston AJ, Sutherland H, Wilson PJ, Psarelli EE, Cox TF, Ranganath LR, Jarvis JC, Gallagher JA.
    JIMD Rep; 2015 Jan 22; 24():45-50. PubMed ID: 25940034
    [Abstract] [Full Text] [Related]

  • 15. Temporal adaptations in the phenylalanine/tyrosine pathway and related factors during nitisinone-induced tyrosinaemia in alkaptonuria.
    Ranganath LR, Hughes AT, Davison AS, Khedr M, Olsson B, Rudebeck M, Imrich R, Norman BP, Bou-Gharios G, Gallagher JA, Milan AM.
    Mol Genet Metab; 2022 Jun 01. PubMed ID: 35680516
    [Abstract] [Full Text] [Related]

  • 16. Metabolic Effects of Increasing Doses of Nitisinone in the Treatment of Alkaptonuria.
    Gertsman I, Barshop BA, Panyard-Davis J, Gangoiti JA, Nyhan WL.
    JIMD Rep; 2015 Jun 01; 24():13-20. PubMed ID: 25665838
    [Abstract] [Full Text] [Related]

  • 17. Characterization of changes in the tyrosine pathway by 24-h profiling during nitisinone treatment in alkaptonuria.
    Ranganath LR, Milan AM, Hughes AT, Davison AS, Khedr M, Norman BP, Bou-Gharios G, Gallagher JA, Gornall M, Jackson R, Imrich R, Rovensky J, Rudebeck M, Olsson B.
    Mol Genet Metab Rep; 2022 Mar 01; 30():100846. PubMed ID: 35242577
    [Abstract] [Full Text] [Related]

  • 18. Alkaptonuria: a very rare metabolic disorder.
    Aquaron R.
    Indian J Biochem Biophys; 2013 Oct 01; 50(5):339-44. PubMed ID: 24772955
    [Abstract] [Full Text] [Related]

  • 19. Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria.
    Hughes JH, Wilson PJM, Sutherland H, Judd S, Hughes AT, Milan AM, Jarvis JC, Bou-Gharios G, Ranganath LR, Gallagher JA.
    J Inherit Metab Dis; 2020 Mar 01; 43(2):259-268. PubMed ID: 31503358
    [Abstract] [Full Text] [Related]

  • 20. Nutritional interventions for patients with alkaptonuria: A minireview.
    Imrich R, Zatkova A, Lukacova O, Sedlakova J, Zanova E, Vlcek M, Penesova A, Radikova Z, Havranova A, Ranganath L.
    Endocr Regul; 2023 Jan 01; 57(1):61-67. PubMed ID: 36966367
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.